China’s CanSino Biologics Inc said on Sunday that its recently developed COVID-19 vaccine has been approved by the country’s drug regulator for emergency use as a booster, potentially benefiting its business.
The inhaled version of Cansino’s adenovirus-vectored COVID-19 vaccine has obtained the green light from the National Medical Products Administration, the company said in a filing on Sunday.
“The approval will have a positive impact on the company’s performance if the vaccine is subsequently purchased and used by relevant government agencies,” CanSino said.
The company cautioned, however, that it will face fierce competition from other vaccines in China that have also obtained government approval or are in clinical trials.
China granted emergency use authorization to Livzon Pharmaceutical Group Inc’s COVID-19 vaccine as a booster, Livzon said on Friday, one of just two new products against the disease the country had cleared in more than a year.
Cansino also said it was uncertain when its vaccine would be able to go to market, since additional administrative approvals are still needed, while sales would depend on the COVID-19 situation at home and abroad, as well as China’s vaccination rate.
China has seen a recent flare-up in COVID outbreaks. The southern tech hub of Shenzhen imposed a weekend lockdown in most parts of the city on Saturday, while the southwestern metropolis of Chengdu put its 21 million people under lockdown on Thursday.
Mainland China reported 1,848 new coronavirus cases for September 3, including both symptomatic and asymptomatic infections, compared with 1,988 new cases a day earlier.
UK scientists working on developing COVID-19 vaccine nasal spray: ReportResearchers have successfully engineered a coronavirus vaccine that can be administered through the nose using a nasal spray, according to a report ... Coronavirus
Russia tests COVID-19 vaccine as nasal spray for children: ReportsRussia has tested a nasal spray form of its COVID-19 vaccine that is suitable for children aged 8-12, and plans to launch the new product in September ... Coronavirus
US authorizes Moderna, Pfizer/BioNTech vaccine targeting omicronThe US Food and Drug Administration on Wednesday authorized the retooled COVID-19 booster shots of both Moderna and Pfizer/BioNTech that target the ... World News
Moderna sues Pfizer/BioNTech for patent infringement over COVID-19 vaccineModerna is suing Pfizer and its German partner BioNTech for patent infringement in the development of the first COVID-19 vaccine approved in the ... Coronavirus
Omicron’s mutations impaired vaccine effectiveness: US CDCAlmost 40 percent of people hospitalized in the US with the COVID-19 subvariant that circulated this spring were vaccinated and boosted, highlighting ... Coronavirus
COVID-19 jab coverage in poorer countries hits 50 pct: Vaccine allianceHalf of people in poorer countries have now received two vaccine doses against COVID-19, a global vaccine alliance said Thursday, hailing progress in ... Coronavirus
UK regulator approves updated Moderna vaccine targeting Omicron variantThe UK’s drug regulator said on Monday it has approved an updated Moderna vaccine against the coronavirus that targets the Omicron variant as well as ... Coronavirus